KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacira BioSciences (PCRX) Tax Provisions (2016 - 2025)

Historic Tax Provisions for Pacira BioSciences (PCRX) over the last 13 years, with Q3 2025 value amounting to $4.1 million.

  • Pacira BioSciences' Tax Provisions fell 1123.64% to $4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.4 million, marking a year-over-year decrease of 4307.21%. This contributed to the annual value of $36.5 million for FY2024, which is 8461.46% up from last year.
  • Pacira BioSciences' Tax Provisions amounted to $4.1 million in Q3 2025, which was down 1123.64% from $2.9 million recorded in Q2 2025.
  • In the past 5 years, Pacira BioSciences' Tax Provisions ranged from a high of $17.7 million in Q2 2024 and a low of -$8.0 million during Q4 2022
  • Its 5-year average for Tax Provisions is $4.2 million, with a median of $4.1 million in 2025.
  • Per our database at Business Quant, Pacira BioSciences' Tax Provisions soared by 1573571.43% in 2021 and then tumbled by 158884.12% in 2023.
  • Quarter analysis of 5 years shows Pacira BioSciences' Tax Provisions stood at -$1.1 million in 2021, then crashed by 645.88% to -$8.0 million in 2022, then soared by 211.1% to $8.8 million in 2023, then grew by 7.18% to $9.5 million in 2024, then plummeted by 56.86% to $4.1 million in 2025.
  • Its Tax Provisions stands at $4.1 million for Q3 2025, versus $2.9 million for Q2 2025 and $3.9 million for Q1 2025.